Literature DB >> 11063837

VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis.

P A Muraro1, T Leist, B Bielekova, H F McFarland.   

Abstract

Effects on adhesion molecules of immune cells might contribute to the mode of action of interferon-beta (IFN-beta) in multiple sclerosis (MS). We have serially monitored the cell surface expression of integrins CD49d (VLA-4) and CD11a (LFA-1) on fresh T lymphocyte subpopulations from 5 MS patients monthly for 2 months prior to treatment and for 3 months on treatment with IFN-beta1b. In parallel, we assessed inflammatory disease activity by monthly contrast-enhanced magnetic resonance imaging (MRI). IFN-beta treatment specifically downregulated CD49d expression on CD8+ and CD4+/CD45RO+ 'memory' T lymphocytes and differentially modulated the proportion of CD4+, CD8+ and CD27+ T cells. These effects may play an important role in the reduction of central nervous system cell trafficking and inflammation in MS.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11063837     DOI： 10.1016/s0165-5728(00)00362-3

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN： 0165-5728            Impact factor:   3.478


  15 in total

1.  Intrathecal effects of daclizumab treatment of multiple sclerosis.

Authors:  B Bielekova; N Richert; M L Herman; J Ohayon; T A Waldmann; H McFarland; R Martin; G Blevins
Journal:  Neurology       Date:  2011-11-09       Impact factor: 9.910

Review 2.  Type I IFN-mediated regulation of IL-1 production in inflammatory disorders.

Authors:  Kristina Ludigs; Valeriy Parfenov; Renaud A Du Pasquier; Greta Guarda
Journal:  Cell Mol Life Sci       Date:  2012-04-24       Impact factor: 9.261

3.  Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

Authors:  Bibiana Bielekova; Marta Catalfamo; Susan Reichert-Scrivner; Amy Packer; Magdalena Cerna; Thomas A Waldmann; Henry McFarland; Pierre A Henkart; Roland Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

Review 4.  Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.

Authors:  A Nandoskar; J Raffel; A S Scalfari; T Friede; R S Nicholas
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

Review 5.  The mechanism of action of interferon-β in relapsing multiple sclerosis.

Authors:  Bernd C Kieseier
Journal:  CNS Drugs       Date:  2011-06-01       Impact factor: 5.749

Review 6.  Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future.

Authors:  Itay Raphael; Johanna Webb; Olaf Stuve; William Haskins; Thomas Forsthuber
Journal:  Expert Rev Clin Immunol       Date:  2014-12-18       Impact factor: 4.473

7.  Expression of VLA-4 molecule in PBMC from patients with hemorrhagic fever with renal syndrome.

Authors:  Ming Xie; Yanying Dong; Linjing He; Huixun Ren; Yuqiang Ji; Shemin Lv
Journal:  Inflamm Res       Date:  2011-02-07       Impact factor: 4.575

Review 8.  The role of alpha-4 integrin in the aetiology of multiple sclerosis: current knowledge and therapeutic implications.

Authors:  William A Sheremata; Alireza Minagar; J Steven Alexander; Timothy Vollmer
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

9.  Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood--brain barrier disruption in multiple sclerosis.

Authors:  Bibiana Bielekova; Nancy Richert; Thomas Howard; Amy N Packer; Gregg Blevins; Joan Ohayon; Henry F McFarland; Claus-Steffen Stürzebecher; Roland Martin
Journal:  Mult Scler       Date:  2009-09-23       Impact factor: 6.312

Review 10.  The role of interferon-β in the treatment of multiple sclerosis and experimental autoimmune encephalomyelitis - in the perspective of inflammasomes.

Authors:  Makoto Inoue; Mari L Shinohara
Journal:  Immunology       Date:  2013-05       Impact factor: 7.397
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.